View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 24, 2021

GSK-Vir’s Covid-19 drug sotrovimab obtains positive EMA opinion

The EMA’s CHMP issues a positive scientific opinion for GSK and Vir Biotechnology’s sotrovimab as early Covid-19 treatment.

The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.

A a SARS-CoV-2 monoclonal antibody, sotrovimab attaches to an epitope on the virus to hinder resistance development.

Integrating Xencor’s Xtend technology, the investigational antibody can potentially achieve increased concentration in the lungs for penetration into Covid-19-affected airway tissues and for an increased half-life.

As per the CHMP opinion, sotrovimab can be used to treat Covid-19 patients aged 12 years and above who weigh at least 40kg, do not need supplemental oxygen and are at risk of disease progression.

The EMA started a review of the antibody last month.

GSK development senior vice-president Christopher Corsico said: “Monoclonal antibody treatments are a critical part of a comprehensive solution to Covid-19, especially as less than 40% of adults across EU member states have received at least one dose of a vaccine to date.

“We are encouraged by this positive scientific opinion from the EMA, as it hopefully brings us closer to making sotrovimab available for patients across Europe.”

The CHMP based its opinion on the review of efficacy and safety results from the Phase III COMET-ICE trial, including an interim analysis and multiple in vitro studies.

Results from the Phase III COMET-ICE trial showed that sotrovimab monotherapy provided an 85% decrease in hospitalisation or death versus placebo, the trial’s primary endpoint.

In a separate development, the CHMP has recommended renewing the conditional marketing authorisation for Gilead Sciences’ Veklury (remdesivir) by a year.

The antiviral Covid-19 treatment received conditional authorisation in July last year to treat Covid-19 in adults and adolescents aged 12 years and above with pneumonia needing supplemental oxygen.

After reviewing new evidence submitted by Gilead, the CHMP found that Veklury’s benefits continue to outweigh its risks and decided to extend the conditional approval.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU